View all available purchase options and get full access to this article. Address reprint requests to Harold F. Dvorak, MD, Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline ...
PURPOSE: We investigated the safety and pharmacokinetics of a recombinant human monoclonal antibody to vascular endothelial growth factor (rhuMAb VEGF) in patients with cancer. PATIENTS AND METHODS: ...
Targeted cancer therapies like CDK4/6, EGFR, VEGFR, and BRAF inhibitors may increase long-term kidney dysfunction risk. Learn ...
ATLANTA-sing a growth factor to stimulate production of circulating endothelial progenitor cells increases the numbers of these vascular regenerative cells, improves mobility, and potentially could ...
The FDA also approved an every 4 week dosing regimen across all approved indications for patients who may not maintain a response on extended dosing intervals following successful initial treatment.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced positive data from the ...
Exercise-induced angiogenesis and lymphangiogenesis offer promising anti-aging benefits by improving vascular and immune system function. A review from researchers in China found that exercise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback